281 related articles for article (PubMed ID: 17224925)
1. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
Reuter CW; Morgan MA; Eckardt A
Br J Cancer; 2007 Feb; 96(3):408-16. PubMed ID: 17224925
[TBL] [Abstract][Full Text] [Related]
2. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
[TBL] [Abstract][Full Text] [Related]
3. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Agulnik M
Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
[TBL] [Abstract][Full Text] [Related]
4. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Brockstein B; Lacouture M; Agulnik M
J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
[TBL] [Abstract][Full Text] [Related]
5. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
6. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
7. Advances in molecular diagnostics and therapeutics in head and neck cancer.
Chai RL; Grandis JR
Curr Treat Options Oncol; 2006 Jan; 7(1):3-11. PubMed ID: 16343364
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
9. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
10. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.
Cruz JJ; Ocaña A; Del Barco E; Pandiella A
Ann Oncol; 2007 Mar; 18(3):421-30. PubMed ID: 16873430
[TBL] [Abstract][Full Text] [Related]
11. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
12. Is EGFR really a therapeutic target in head and neck cancers?
Agarwal V; Subash A; Nayar RC; Rao V
J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Sharafinski ME; Ferris RL; Ferrone S; Grandis JR
Head Neck; 2010 Oct; 32(10):1412-21. PubMed ID: 20848399
[TBL] [Abstract][Full Text] [Related]
14. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Cohen EE; Lingen MW; Martin LE; Harris PL; Brannigan BW; Haserlat SM; Okimoto RA; Sgroi DC; Dahiya S; Muir B; Clark JR; Rocco JW; Vokes EE; Haber DA; Bell DW
Clin Cancer Res; 2005 Nov; 11(22):8105-8. PubMed ID: 16299242
[TBL] [Abstract][Full Text] [Related]
15. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
Iberri DJ; Colevas AD
Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236
[TBL] [Abstract][Full Text] [Related]
16. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
[TBL] [Abstract][Full Text] [Related]
17. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
[TBL] [Abstract][Full Text] [Related]
18. Promising new molecular targeted therapies in head and neck cancer.
Dorsey K; Agulnik M
Drugs; 2013 Mar; 73(4):315-25. PubMed ID: 23440867
[TBL] [Abstract][Full Text] [Related]
19. EGFR-targeting monoclonal antibodies in head and neck cancer.
Astsaturov I; Cohen RB; Harari PM
Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
